See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I was unable to find a specific projection of Apotex's projected Ruxolitinib market share. However, I can provide some context about the drug and Apotex's role in its market.

Ruxolitinib is a medication used to treat myelofibrosis and polycythemia vera, two types of blood cancer. It is marketed under the brand name Jakafi by Incyte Corporation, which holds the patent for the drug. Apotex, a Canadian pharmaceutical company, is one of the generic manufacturers of Ruxolitinib.

In terms of market share, Incyte Corporation held a significant portion of the Ruxolitinib market in 2020, with Jakafi generating sales of $1.7 billion in that year alone [1]. However, with the expiration of Ruxolitinib's patent, generic manufacturers like Apotex have entered the market, which may impact Incyte's market share.

According to DrugPatentWatch.com, Ruxolitinib's patent expired in the United States in November 2020 [2]. This means that other pharmaceutical companies can now produce and sell generic versions of the drug, potentially increasing competition and reducing prices. As a result, Apotex and other generic manufacturers may capture a portion of the Ruxolitinib market.

However, it is challenging to provide a specific projection of Apotex's market share without additional information. Factors such as pricing strategies, marketing efforts, and distribution channels will all play a role in determining Apotex's market share in the Ruxolitinib market.

Sources:

* [1] Incyte Corporation. (2021). Incyte Reports Fourth Quarter and Full Year 2020 Financial Results. <https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2020-financial>.
* [2] DrugPatentWatch.com. (2021). Ruxolitinib (Jakafi). <https://www.drugpatentwatch.com/drugs/ruxolitinib>.